Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RAPT 
RAPT Therapeutics Inc (RAPT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: RAPT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.17
1 Year Target Price $30.17
| 1 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.86% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 485.22M USD | Price to earnings Ratio - | 1Y Target Price 30.17 |
Price to earnings Ratio - | 1Y Target Price 30.17 | ||
Volume (30-day avg) 7 | Beta 0.23 | 52 Weeks Range 5.66 - 32.35 | Updated Date 10/17/2025 |
52 Weeks Range 5.66 - 32.35 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.24% | Return on Equity (TTM) -77.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 315466805 | Price to Sales(TTM) 411.22 |
Enterprise Value 315466805 | Price to Sales(TTM) 411.22 | ||
Enterprise Value to Revenue 677.37 | Enterprise Value to EBITDA -10.73 | Shares Outstanding 16537794 | Shares Floating 3915819 |
Shares Outstanding 16537794 | Shares Floating 3915819 | ||
Percent Insiders 0.42 | Percent Institutions 102.56 |
Upturn AI SWOT
RAPT Therapeutics Inc
Company Overview
History and Background
RAPT Therapeutics, Inc. was founded in 2015. It is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing oral small molecule therapies for inflammatory diseases. The company went public in 2020.
Core Business Areas
- Drug Discovery and Development: RAPT Therapeutics focuses on identifying and developing oral small molecule therapeutics targeting key immune drivers.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates in various inflammatory diseases.
Leadership and Structure
RAPT Therapeutics is led by a management team with experience in drug development and the biopharmaceutical industry. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- FLX475: FLX475 is a CCR4 antagonist being developed for the treatment of cancer. It is currently in phase 1/2. Competition includes companies developing similar CCR4 antagonists and other immuno-oncology therapies. Revenue from this product currently zero.
- Market Share: Not Applicable
- Market Share: Not Applicable
- RPT193: RPT193 is an oral small molecule CCR4 antagonist designed to treat atopic dermatitis and other inflammatory diseases. It is currently in Phase 1. Competition includes companies developing therapies for atopic dermatitis such as Sanofi (SNY) and Regeneron (REGN) with Dupixent. Revenue from this product currently zero.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high regulatory hurdles, and significant investment in research and development. There is a growing demand for novel therapies to treat inflammatory diseases.
Positioning
RAPT Therapeutics is positioned as a company focused on developing targeted oral therapies for inflammatory diseases, which may offer advantages over existing treatments.
Total Addressable Market (TAM)
The TAM for inflammatory disease therapies is substantial, projected to reach billions of dollars globally. RAPT is positioned to capture a share of this market with its innovative drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting key immune drivers
- Oral small molecule platform
- Experienced management team
Weaknesses
- Clinical-stage company with no approved products
- Reliance on successful clinical trial outcomes
- High cash burn rate
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new disease indications
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- Sanofi (SNY)
- Regeneron (REGN)
- Bristol Myers Squibb (BMY)
Competitive Landscape
RAPT Therapeutics competes with larger, established pharmaceutical companies in the inflammatory disease market. Its advantages lie in its novel drug candidates and oral small molecule platform.
Growth Trajectory and Initiatives
Historical Growth: RAPT Therapeutics' historical growth is defined by its research and development progress, clinical trial milestones, and successful IPO.
Future Projections: Future growth depends on the success of its clinical programs and potential partnerships. Analyst estimates vary and are subject to change.
Recent Initiatives: Recent initiatives include advancing RPT193 into Phase 1 and continuing FLX475 clinical trials.
Summary
RAPT Therapeutics is a clinical-stage biopharmaceutical company with promising novel drug candidates. Success hinges on positive clinical trial outcomes. It faces competition from established players and requires sufficient funding for continued development. It should focus on strategic partnerships and efficient clinical execution.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on available information and may be subject to change. Consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About RAPT Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-10-31 | CEO, President & Director Dr. Brian Russell Wong M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.rapt.com |
Full time employees 61 | Website https://www.rapt.com | ||
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.